Table 4.
Top 10 metabolites of the AA and CRC validation cohorts.
| Validation CRC | ||||
| Class | Metabolite |
Control
(n = 29) |
CRC
(n = 48) |
p-Value |
| PC aa | PC aa C32:3 | 0.44 ± 0.14 | 0.33 ± 0.09 | <0.001 |
| PC ae | PC ae C36:2 | 14.60 ± 3.44 | 11.52 ± 3.51 | <0.001 |
| LysoPC | LysoPC a C17:0 | 3.01 ± 0.76 | 2.31 ± 0.77 | <0.001 |
| LysoPC a C24:0 | 0.22 ± 0.10 | 0.17 ± 0.10 | <0.001 | |
| LysoPC a C28:0 | 0.80 ± 0.27 | 0.24 ± 0.33 | 0.002 | |
| LysoPC a C28:1 | 0.65 ± 0.27 | 0.48 ± 0.24 | 0.001 | |
| SM | SM (OH) C22:1 | 19.27 ± 4.18 | 16.12 ± 4.60 | 0.001 |
| SM (OH) C22:2 | 19.10 ± 3.48 | 15.50 ± 4.85 | 0.001 | |
| SM (OH)/SM (non-OH) | 0.17 ± 0.02 | 0.15 ± 0.03 | <0.001 | |
| Total SM (OH) | 54.86 ± 10.38 | 45.62 ± 12.96 | <0.001 | |
| Validation AA | ||||
| Class | Metabolite |
Control
(n = 28) |
AA
(n = 48) |
p-Value |
| PC aa | PC aa C38:6 | 60.44 ± 18.06 | 76.49 ± 20.76 | 0.001 |
| PC ae | PC ae C38:6 | 5.92 ± 1.53 | 7.19 ± 1.60 | 0.001 |
| PC ae C40:6 | 4.23 ± 1.02 | 5.05 ± 1.00 | 0.001 | |
| SM | SM C18:1 | 12.19 ± 3.37 | 14.72 ± 3.04 | 0.001 |
| SM C24:1 | 55.63 ± 12.91 | 64.34 ± 10.72 | 0.002 | |
| SM (OH) C22:2 | 13.51 ± 3.54 | 16.33 ± 3.51 | 0.001 | |
| SM (OH) C24:1 | 1.45 ± 0.35 | 1.71 ± 0.37 | 0.003 | |
| Total SM | 308.06 ± 61.13 | 347.89 ± 49.01 | 0.003 | |
| Total SM (OH) | 40.08 ± 10.05 | 47.17 ± 9.52 | 0.003 | |
| AA | Cit/Arg | 0.22 ± 0.06 | 0.27 ± 0.07 | 0.001 |
AA, amino acid; LysoPC, monoacyl-glycerophosphocholine; PC aa, diacyl-glycerophosphocholine; PC ae, alky-acyl-glycerophosphocholine; SM, sphingomyelin; data are expressed in µM (except for ratios) as means ± standard deviation; p-values are assessed by t-test or Mann–Whitney U test; p-values < 0.05 were considered to indicate statistical significance and are marked in bold.